Nycomed sues Glenmark over ANDA for fluticasone lotion
This article was originally published in Scrip
Executive Summary
Nycomedhas filed a patent infringement suit in the eastern district court of New York against Glenmark Generics' US subsidiary over the latter's ANDA for fluticasone propionate 0.05% lotion. The product is a generic version of Nycomed's Cutivate lotion, used for inflammatory and pruritic manifestations of atopic dermatitis. Glenmark believes it may be the first applicant to have filed an ANDA for this product with a paragraph IV certification. Glenmark will be entitled to a 180-day marketing exclusivity, should it successfully challenge Nycomed's patent. Cutivate 0.05% lotion reported annual sales of about $33 million in the US, IMS sales data to the end of September show.